A newly formed biotech launched out of George Daley’s Harvard lab adds global players to its syndicate, bringing its haul to $83M
The prospect of finding new drugs that can modulate RNA proteins to help fight diseases has brought in a pair of new backers for 28-7, an upstart biotech with a lead program out of Harvard.
Paris-based Sofinnova Partners and Osage University Partners have chipped in an extra $15 million to bring the biotech’s launch round to $82.75 million. They’re joining a syndicate that includes MPM and Novartis, which kicked off the public festivities last fall.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
